Medicare Expands Coverage for Obesity Medications in 2023
Beginning this week, Medicare offers coverage for obesity medications, providing seniors a new avenue for weight management with GLP-1 drugs. Patients eligible for this coverage will have a monthly copay of $50, broadening access to medications previously out of reach for many seniors, according to industry insights from Novo Nordisk and Eli Lilly.
Traditionally, Medicare Part D plans covered GLP-1 drugs for treating diabetes and heart disease, but not for obesity. The new Bridge demonstration program bypasses existing legal constraints, granting temporary coverage for obesity management, including individuals with conditions such as prediabetes or uncontrolled hypertension.
The impact of this program is significant, considering Medicare's 69 million beneficiaries, with several million expected to enroll, as noted by Chris Klomp of the Centers for Medicare & Medicaid Services (CMS). Estimates from Novo Nordisk and Eli Lilly suggest that 15 to 20 million beneficiaries could benefit from these weight loss drugs.
Providers will need to submit prior authorization requests to confirm eligibility, potentially leading to increased demand and operational challenges for medical clinics and pharmacies. This new coverage may create administrative burdens and affect workflow efficiency within the healthcare system.
The copay structure under the Bridge program will not contribute to a patient's Part D deductible or cap on out-of-pocket expenses, as noted by Georgetown University's Rachel Schmidt. However, the $600 annual cost could still be prohibitive for some seniors, highlighting a potential barrier to access.
The program, funded by taxpayer dollars and copays rather than private insurers, simplifies the eligibility confirmation process with clinicians. It expands eligibility to more patients based on clinical criteria, such as a body mass index of 35 or higher, or lower with related health issues.
The new offering could increase competition between pharmaceutical leaders like Novo Nordisk and Eli Lilly, anticipating significant market growth. Analysts forecast substantial revenue opportunities, with potential healthcare cost savings if these treatments prove effective. However, the future of the Bridge program post-2027 remains uncertain without regulatory modifications, as legislative hurdles continue to challenge permanent policy changes.